Form 4: Inmune Bio CEO Raymond Tesi Acquires Shares and Warrants in $13 Million Direct Offering

Raymond Joseph Tesi, CEO of Inmune Bio, Inc., reports acquisition of common stock and warrants through a registered direct offering.

Summary

• Raymond Joseph Tesi, the President and CEO of Inmune Bio, Inc., reported the acquisition of 15,380 shares of common stock and warrants to purchase 15,380 shares.
• The transactions occurred on September 12, 2024.
• The common stock was purchased at $6.375 per share.
• The warrants have an exercise price of $6.40 per share and expire on March 16, 2030, with potential extensions for insiders during blackout periods.
• The shares and warrants were acquired through a registered direct offering at a price of $6.50, for an aggregate purchase price of $13,000,000 pursuant to a securities purchase agreement dated September 12, 2024.
• Following the reported transaction, Tesi directly owns 1,554,106 shares of Inmune Bio, Inc.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the CEO's significant investment in the company, signaling confidence. However, it's a routine regulatory filing, so the impact is limited.

Positives

• The CEO's purchase of shares and warrants may signal confidence in the company's future prospects.
• The registered direct offering provides Inmune Bio with $13,000,000 in capital.

Future Outlook

The document does not contain explicit forward-looking statements beyond the warrant's exercisability and expiration details.

Industry Context

Insider buying is often viewed positively, suggesting management's belief in the company's prospects. Direct offerings are a common way for companies, especially in the biotech sector, to raise capital.

Stakeholder Impact

• Shareholders may view the CEO's purchase positively.
• The capital raised could support the company's operations and development programs.

Key Dates